Where we end up is important not the upfront.
We didn't wait all these years and kept faith for 200-300m valuation, let's be serious guys.
A licensing agreement is a reflection of trust in science by other Pharma company who have made a decision to partner after a full on due diligence and know way more about science than any of us.
I am really interested to see the deal structure as I won't be surprised to see Dimerix trading around 1bn post March results (assuming it's positive and it's a global agreement).
Ann: Trading Halt, page-9
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $280.6M | |||
| Open | High | Low | Value | Volume |
| 51.5¢ | 54.5¢ | 51.0¢ | $1.715M | 3.301M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 365433 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 51.5¢ | 19658 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |